$APYX
Apyx Medical Corp Stock $apyx

$apyx Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000071913524000026 Filed on May 09, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$12.15M	$10.24M
YoY Change	-10.47%	-15.63%
Cost Of Revenue	$4.656M	$4.295M
YoY Change	8.53%	-6.0%
Gross Profit	$7.493M	$5.949M
YoY Change	-19.25%	-21.44%
Gross Profit Margin	61.68%	58.07%
Selling, General & Admin	$4.838M	$4.897M
YoY Change	-10.04%	-6.81%
% of Gross Profit	64.57%	82.32%
Research & Development	$1.424M	$1.397M
YoY Change	18.77%	24.62%
% of Gross Profit	19.0%	23.48%
Depreciation & Amortization	$156.0K	$157.0K
YoY Change	3.31%	-22.66%
% of Gross Profit	2.08%	2.64%
Operating Expenses	$13.04M	$12.56M
YoY Change	-1.26%	-4.7%
Operating Profit	-$5.547M	-$6.615M
YoY Change	349.15%	17.89%
Interest Expense	$1.427M	$1.396M
YoY Change	162.8%	496.58%
% of Operating Profit
Other Income/Expense, Net	-$989.0K	-$922.0K
YoY Change	-450.71%	390.43%
Pretax Income	-$6.536M	-$7.537M
YoY Change	585.83%	29.97%
Income Tax	$50.00K	$53.00K
% Of Pretax Income
Net Earnings	-$6.556M	-$7.576M
YoY Change	559.56%	117.51%
Net Earnings / Revenue	-53.96%	-73.96%
Basic Earnings Per Share	-$0.19	-$0.22
Diluted Earnings Per Share	-$0.19	-$0.22
COMMON SHARES
Basic Shares Outstanding	34.64M shares	34.64M shares
Diluted Shares Outstanding	34.64M shares	34.64M shares

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$32.68M	$37.28M
YoY Change	76.84%	129.36%
Cash & Equivalents	$32.68M	$37.28M
Short-Term Investments
Other Short-Term Assets	$1.960M	$2.362M
YoY Change	-36.77%	-67.86%
Inventory	$9.324M	$9.795M
Prepaid Expenses
Receivables	$12.71M	$12.49M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$56.67M	$61.93M
YoY Change	7.16%	17.54%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.918M	$1.779M
YoY Change	-9.44%	-15.65%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.811M	$1.893M
YoY Change	-5.08%	52.78%
Total Long-Term Assets	$8.723M	$8.785M
YoY Change	-8.6%	114.27%
TOTAL ASSETS
Total Short-Term Assets	$56.67M	$61.93M
Total Long-Term Assets	$8.723M	$8.785M
Total Assets	$65.39M	$70.71M
YoY Change	4.75%	24.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.348M	$2.103M
YoY Change	-11.66%	10.39%
Accrued Expenses	$7.493M	$7.918M
YoY Change	6.91%	17.18%
Deferred Revenue		$515.0K
YoY Change		-51.09%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$20.00K	$20.00K
YoY Change	-99.78%	-99.77%
Total Short-Term Liabilities	$10.64M	$10.56M
YoY Change	-44.09%	-43.02%
LONG-TERM LIABILITIES
Long-Term Debt	$33.63M	$33.41M
YoY Change	53277.78%	49026.47%
Other Long-Term Liabilities	$192.0K	$194.0K
YoY Change	3.78%	4.86%
Total Long-Term Liabilities	$33.82M	$33.60M
YoY Change	18181.08%	18062.16%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.64M	$10.56M
Total Long-Term Liabilities	$33.82M	$33.60M
Total Liabilities	$50.47M	$50.25M
YoY Change	96.41%	144.29%
SHAREHOLDERS EQUITY
Retained Earnings	-$68.58M	-$62.02M
YoY Change	70.55%	58.15%
Common Stock	$35.00K	$35.00K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$14.75M	$20.25M
YoY Change
Total Liabilities & Shareholders Equity	$65.39M	$70.71M
YoY Change	4.75%	24.53%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	-$6.556M	-$7.576M
YoY Change	559.56%	117.51%
Depreciation, Depletion And Amortization	$156.0K	$157.0K
YoY Change	3.31%	-22.66%
Cash From Operating Activities	-$4.329M	-$6.341M
YoY Change	-10.78%	233.74%
INVESTING ACTIVITIES
Capital Expenditures	$289.0K	$35.00K
YoY Change	85.26%	-68.18%
Acquisitions
YoY Change
Other Investing Activities	$0.00
YoY Change	-100.0%
Cash From Investing Activities	-$289.0K	-$35.00K
YoY Change	-104.06%	-68.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-5.000K	-$5.000K
YoY Change	-110.87%	-100.06%
NET CHANGE
Cash From Operating Activities	-4.329M	-$6.341M
Cash From Investing Activities	-289.0K	-$35.00K
Cash From Financing Activities	-5.000K	-$5.000K
Net Change In Cash	-4.623M	-$6.370M
YoY Change	-300.56%	-205.06%
FREE CASH FLOW
Cash From Operating Activities	-$4.329M	-$6.341M
Capital Expenditures	$289.0K	$35.00K
Free Cash Flow	-$4.618M	-$6.376M
YoY Change	-7.79%	217.21%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	36214000	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	20460000	usd
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-7590000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34643926	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34643926	shares
CY2024Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4295000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4569000	usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	5949000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	7573000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1397000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1271000	usd
CY2024Q1	us-gaap	Professional Fees ProfessionalFees	1574000	usd
CY2023Q1	us-gaap	Professional Fees ProfessionalFees	1740000	usd
CY2024Q1	us-gaap	Salaries And Wages SalariesAndWages	4696000	usd
CY2023Q1	us-gaap	Salaries And Wages SalariesAndWages	4918000	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4897000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5255000	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	12564000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	13184000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6615000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5611000	usd
CY2024Q1	us-gaap	Interest Income Operating InterestIncomeOperating	495000	usd
CY2023Q1	us-gaap	Interest Income Operating InterestIncomeOperating	51000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	1396000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	234000	usd
CY2024Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-21000	usd
CY2023Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-5000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-922000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-188000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7537000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5799000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	53000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2267000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-7590000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-3532000	usd
CY2024Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-14000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-49000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-7576000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3483000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.22
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	37793000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1367000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	586000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-3532000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	26922000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1128000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-7590000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-3532000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	157000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	203000	usd
CY2024Q1	apyx	Provision For Inventory Obsolescence ProvisionForInventoryObsolescence	7000	usd
CY2023Q1	apyx	Provision For Inventory Obsolescence ProvisionForInventoryObsolescence	0	usd
CY2024Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-20000	usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1128000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1367000	usd
CY2024Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-142000	usd
CY2024Q1	apyx	Non Cash Lease Expense NonCashLeaseExpense	31000	usd
CY2023Q1	apyx	Non Cash Lease Expense NonCashLeaseExpense	0	usd
CY2024Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	221000	usd
CY2023Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	67000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1478000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-837000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-241000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-858000	usd
CY2024Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	0	usd
CY2023Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	207000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-138000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-879000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-599000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-776000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1573000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1435000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6341000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1881000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	35000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	110000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-35000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-110000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	9289000	usd
CY2024Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2023Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	1754000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	586000	usd
CY2024Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	5000	usd
CY2023Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	9000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-5000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8112000	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-58000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6370000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6063000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	43652000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10192000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	37282000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16255000	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	1175000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	1000	usd
CY2024Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	6000	usd
CY2023Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	125000	usd
CY2024Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has reclassified certain amounts presented in the prior period to conform to the current period presentation. These amounts primarily relate to management salaries that were previously included within salaries and related costs and are now included within research and development. These reclassifications had no impact on previously reported net loss, accumulated deficit or cash flows for the periods presented.</span></div>
CY2024Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	3941000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	4112000	usd
CY2024Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	2338000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	2257000	usd
CY2024Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4396000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4429000	usd
CY2024Q1	us-gaap	Inventory Gross InventoryGross	10675000	usd
CY2023Q4	us-gaap	Inventory Gross InventoryGross	10798000	usd
CY2024Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	880000	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	875000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	9795000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	9923000	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1277000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	829000	usd
CY2024Q1	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	593000	usd
CY2023Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1545000	usd
CY2024Q1	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	576000	usd
CY2023Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	1489000	usd
CY2024Q1	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	432000	usd
CY2023Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	445000	usd
CY2024Q1	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	3401000	usd
CY2023Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	3521000	usd
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	328000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	518000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	515000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	488000	usd
CY2024Q1	apyx	Other Accrued Expenses And Liabilities Current OtherAccruedExpensesAndLiabilitiesCurrent	955000	usd
CY2023Q4	apyx	Other Accrued Expenses And Liabilities Current OtherAccruedExpensesAndLiabilitiesCurrent	826000	usd
CY2024Q1	apyx	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	8077000	usd
CY2023Q4	apyx	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	9661000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	2216000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	35284000	usd
CY2024Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	37500000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-7576000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7576000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3483000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-3483000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34644000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34644000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34598000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34598000	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.22
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1128000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1367000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7342883	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.31
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1468929	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.36
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	569	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.50
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	298079	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	7.63
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8513164	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.58
CY2024Q1	apyx	Stock Issued During Period Shares Stock Swaps Equity Instruments Received StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived	531	shares
CY2024Q1	apyx	Stock Issued During Period Shares Stock Swaps StockIssuedDuringPeriodSharesStockSwaps	38	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.040
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.042
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.921
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.943
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	53000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2267000	usd
CY2024Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.007
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.391
CY2023Q1	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	-2100000	usd
CY2024Q1	us-gaap	Purchase Obligation PurchaseObligation	2700000	usd
CY2024Q1	apyx	Purchase Obligation Expected Purchase Period PurchaseObligationExpectedPurchasePeriod	P12M
CY2024Q1	apyx	Related Party Transaction Number Of Related Parties RelatedPartyTransactionNumberOfRelatedParties	2	related_party
CY2024Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2024Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10244000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6615000	usd
CY2024Q1	us-gaap	Interest Income Operating InterestIncomeOperating	495000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	1396000	usd
CY2024Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-21000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	53000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12142000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5611000	usd
CY2023Q1	us-gaap	Interest Income Operating InterestIncomeOperating	51000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	234000	usd
CY2023Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-5000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2267000	usd
CY2024Q1	apyx	Total Revenue Percent TotalRevenuePercent	0.319
CY2023Q1	apyx	Total Revenue Percent TotalRevenuePercent	0.269
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10244000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12142000	usd

Files In Submission

Name	View Source	Status
0000719135-24-000026-index-headers.html	Edgar Link	pending
0000719135-24-000026-index.html	Edgar Link	pending
0000719135-24-000026.txt	Edgar Link	pending
0000719135-24-000026-xbrl.zip	Edgar Link	pending
a2024q110-kexhibit311.htm	Edgar Link	pending
a2024q110-kexhibit312.htm	Edgar Link	pending
a2024q110-kexhibit321.htm	Edgar Link	pending
a2024q110-kexhibit322.htm	Edgar Link	pending
apyx-20240331.htm	Edgar Link	pending
apyx-20240331.xsd	Edgar Link	pending
apyx-20240331_g1.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
apyx-20240331_def.xml	Edgar Link	unprocessable
apyx-20240331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
apyx-20240331_htm.xml	Edgar Link	completed
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
apyx-20240331_lab.xml	Edgar Link	unprocessable
apyx-20240331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$APYX
Apyx Medical Corp Stock $apyx

2024 Q2 Form 10-Q Financial Statement

#000071913524000026 Filed on May 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APYX Apyx Medical Corp Stock $apyx

2024 Q2 Form 10-Q Financial Statement

#000071913524000026 Filed on May 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APYX
Apyx Medical Corp Stock $apyx